<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-2-09-04-2026-shutterstock_1349493995-430x241.jpg"/>
                                    
                                    <figcaption>The acquisition includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in Asia Pacific. Credit: MiniStocker / Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                        
<p>Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).</p>



<p>The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>Immuno-oncology (IO) - Thematic Intelligence </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Under the deal, Everest Medicines will pay a total consideration of $250m in three instalments: $150m at closing, and two further $50m payments due in the first quarters of 2028 and 2029, subject to agreed conditions precedent.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Hasten Biopharmaceuticals (Asia) will also pay a refundable deposit of 200m yuan ($29.2m) to Everest Medicines within ten days after closing.</p>



<p>Upon closing, Everest Medicines will consolidate the financial results of Hasten Biopharmaceuticals.</p>



<p>The acquisition includes trademark and broad commercial rights and marketing authorisation holder (MAH) rights for 14 branded chronic disease products that are owned by Hasten Biopharmaceuticals in various Asia Pacific jurisdictions.</p>



<p>In December 2025, Hasten Biopharmaceuticals posted normalised revenue of $82.23m and EBITDA of $27.27m.</p>



<p>The company commercialises prescription pharmaceuticals with a focus on chronic and acute/critical care, targeting the metabolic and cardiovascular segments.</p><div id="slot-two"></div>



<p>Everest Medicines has a pipeline that is focused on chronic disease therapeutic areas such as cardiovascular, kidney, and metabolic illnesses.</p>



<p>Its products, including Nefecon, Velsipity, and Xerava, are advancing through new drug application and reimbursement processes in Asian markets.</p>



<p>The company expects the acquisition to further expedite regional product commercialisation and overseas revenue generation.</p>



<p>It will also expand Everest Medicines’ existing commercialisation capabilities from China to the Asia Pacific, supporting market entry and the development of infrastructure needed for international growth.</p>



<p>In February 2026, Everest Medicines signed an exclusive licence agreement with Micot to commercialise MT1013 in China and the Asia Pacific (excluding Japan).</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>

512290

159316

516820

<p>EverSea Medicines, a subsidiary of Everest Medicines, has signed a share purchase agreement to acquire Hasten Biopharmaceuticals for $250 million. The deal includes MAH rights, trademarks, and commercial rights for 14 chronic disease products in the Asia Pacific region. The acquisition aims to enhance Everest Medicines' market presence and commercial capabilities. Hasten Biopharmaceuticals reported normalized revenue of $82.23 million and EBITDA of $27.27 million in December 2025. The acquisition is expected to expedite product commercialization and support international growth.</p>

Pharmaceutical Technology

Guotai CSI Bio-medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ICBCCS SSE STAR Biology and Medicine ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Huaan Hang Seng Biotech ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Tianhong CNI BIOMEDICINE ETF

Penghua CSI HK Connect Health Care Composite ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng Health Care ETF(QDII)

GF CSI HK Innovative Drugs Industry ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CNI HK Connect Innovative Drugs ETF

Yinhua CSI Innovative Drugs Industry ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

E Fund CSI Biotechnology Theme ETF

EverSea Medicines to acquire Hasten Biopharmaceuticals